Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

Abstract

Aim: The cost–effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed.

Materials and methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost–effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY).

Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses.

Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.

People

Critchlow, Simone

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Bullement, Ash

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Crabb, Simon

Author

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Jones, Robert

Author

Elyan, Benjamin M.P. and Tan, Beatrix and Lambourg, Emilie and McAllister, David A. and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. and Bell, Samira (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, 18 (5): sfaf084. ISSN 2048-8505

Elyan, Benjamin M.P. and Sullivan, Michael K. and Hedley, James and De La Mata, Nicole and Webster, Angela C. and Venugopal, Balaji and Jones, Rob J. and Lang, Ninian N. and Mark, Patrick B. and Lees, Jennifer S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2: 57. ISSN 2731-9377

Rescigno, Pasquale and Porta, Nuria and Finneran, Laura and Riisnaes, Ruth and Figueiredo, Ines and Carreira, Suzanne and Flohr, Penny and Miranda, Susana and Bertan, Claudia and Ferreira, Ana and Crespo, Mateus and Rodrigues, Daniel Nava and Gurel, Bora and Nobes, Jenny and Crabb, Simon and Malik, Zafar and Ralph, Christy and McGovern, Ursula and Hoskin, Peter and Jones, Robert J. and Birtle, Alison and Gale, Joanna and Sankey, Peter and Jain, Suneil and McLaren, Duncan and Chadwick, Eliot and Espinasse, Aude and Hall, Emma and de Bono, Johann (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205: 114103. ISSN 0959-8049

See full publications list

Christoforou, Katerina

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Amin, Amerah

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Xiao, Ying

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Kapetanakis, Venediktos

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Benedict, Ágnes

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Chang, Jane

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Kearney, Mairead

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list

Eccleston, Anthony

Author

Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

See full publications list
Texts
349:360
Preview of 305260.pdf
305260.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB) | Preview
Information
Library

View Item